Optimizing therapy with 6-mercaptopurine and azathioprine: To measure or not to measure?

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 5, 2010, Pages 275-279

  Deshpande, Amar R ^a   Abreu, María T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; MERCAPTOPURINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW TOXICITY; CROHN DISEASE; DNA SYNTHESIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG METABOLISM; EDITORIAL; FEVER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; PANCREATITIS; PRIORITY JOURNAL; T LYMPHOCYTE; ULCERATIVE COLITIS;

EID: 77956253035     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X10376121     Document Type: Editorial

References (24)

1. Bowen, G.E., Irons, G.V., Rhodes, J.B. and Kirsner, J.B. ( 1966) Early experiences with azathioprine in ulcerative colitis: a note of caution. JAMA 195: 460-464.
2. Burchenal, J.H., Murphy, M.L., Ellison, R.R., Sykes, M.P., Tan, T.C., Leone, L.A. et al. (1953) Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukaemia and allied diseases. Blood 8: 965-999.
3. Colombel, J.F., Ferrari, N., Debuysere, H., Marteau, P., Gendre, J.P., Bonaz, B. et al. (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118: 1025-1030.
4. Cuffari, C., Dassopoulos, T., Turnbough, L., Thompson, R.E. and Bayless, T.M. ( 2004) Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2: 410-417.
5. Dubinsky, M.C., Lamothe, S., Yang, H.Y., Targan, S.R., Sinnett, D., Theoret, Y. et al. (2000) Pharmacogenetics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705-713.
6. Dubinsky, M.C., Reyes, E., Ofman, J., Chiou, C.F., Wade, S. and Sandborn, W.J. ( 2005) A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 100: 2239-2247.
7. Dubinsky, M.C., Yang, H., Hassard, P.V., Seidman, E.G., Kam, L.Y., Abreu, M.T. et al. (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122: 904-915.
8. Elion, G.B. and Hitchings, G.H. ( 1975) Azathioprine, In: Evenson, M.A. (ed.), Handbook of Experimental Pharmacology, Springer-Verlag: New York.
9. Hitchings, G.H., Elion, G.B., Falco, E.A., Russell, P.B. and Vanderwerff, H. ( 1950) Studies on analogs of purines and pyrimidines. Ann N Y Acad Sci 52: 1318-1335.
10. Lennard, L. ( 1992) The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43: 329-339.
11. Lennard, L., Rees, C.A., Lilleyman, J.S. and Maddocks, J.L. ( 1983) Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16: 359-363.
12. Lennard, L., van Loon, J.A., Lilleyman, J.S. and Weinshilboum, R.M. ( 1987) Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41: 18-25.
13. Lewis, J.D., Abramson, O., Pascua, M., Liu, L., Asakura, L.M., Velayos, F.S. et al. (2009) Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol 7: 1195-1201.
14. Osterman, M.T., Kundu, R., Lichtenstein, G.R. and Lewis, J.D. ( 2006) Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130: 1047-1053.
15. Present, D.H., Korelitz, B.I., Wisch, N., Glass, J.L., Sachar, D.B. and Pasternack, B.S. ( 1980) Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302: 981-987.
16. Shaye, O.A., Yadegari, M., Abreu, M.T., Poordad, F., Simon, K., Simon, K. et al. (2007) Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 102: 2488-2494.
17. Sparrow, M.P., Hande, S.A., Friedman, S., Cao, D. and Hanauer, S.B. ( 2007) Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 5: 209-214.
18. Sparrow, M.P., Hande, S.A., Friedman, S., Lim, W.C., Reddy, S.I., Cao, D. et al. (2005) Allopurinol safely and effectively optimizes thioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 22: 441-446.
19. Tiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D. et al. (2003) CD28-dependent Rac 1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111: 1133-1145.
20. van Asseldonk, D.P., Kanis, B.M., de Boer, N.K. and van Bodegraven, A.A. (2009) Leukopenia due to parvovirus B 19 in a Crohn's disease patient using azathioprine. Digestion 79: 211-214.
21. Weinshilboum, R.M. and Sladek, S.L. ( 1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methytransferase activity. Am J Hum Genet 32: 651-662.
22. Willoughby, J.T., Beckett, J., Kumar, P.J. and Dawson, A.M. ( 1971) Controlled trial of azathioprine in Crohn's disease. Lancet 298: 944-947.
23. Winter, J., Walker, A., Shapiro, D., Gaffney, D., Spooner, R.J. and Mills, P.R. ( 2004) Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 20: 593-599.
24. Winter, J.W., Gaffney, D., Shapiro, D., Spooner, R.J., Marinaki, A.M., Sanderson, A.M. et al. (2007) Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 25: 1069-1077.